Core Insights - Kestra Medical Technologies, Ltd. reported preliminary financial results for Q2 fiscal 2026, indicating strong growth in revenue and gross margin [1][4] Financial Performance - Revenue is expected to be between $22.2 million and $22.6 million, reflecting a 52% increase at the midpoint compared to $14.7 million in the same period last year [6] - Gross profit is projected to be between $11.0 million and $11.4 million, up from $5.8 million in the prior year period [6] - Gross margin is anticipated to reach 50.0%, compared to 39.6% in the previous year [6] - Loss from operations is expected to be between $31.6 million and $32.0 million, an increase from $19.1 million in the prior year [6] - Cash and cash equivalents are projected to be approximately $175 million [6] Market Position and Strategy - The company is experiencing sustained commercial momentum as it expands in the wearable defibrillator market [2] - The improvement in gross margin is attributed to attractive unit economics and positive leverage in the business model [2]
Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results